Risk of Reactivation of Latent HBV Hepatitis in Patients Under Neurosurgical TreatmentYoshikazu Ogawa1* and Teiji Tominaga2
- *Corresponding Author:
- Yoshikazu Ogawa
Departments of Pathology and Neurosurgery
Tohoku University Graduate School of Medicine
1-1 Seiryo-machi, Aoba-ku, Sendai
Miyagi 980-8574, Japan
E-mail: [email protected]
Received date: Oct 04, 2016; Accepted date: Oct 18, 2016; Published date: Oct 20, 2016
Citation: Ogawa Y, Tominaga T (2016) Risk of Reactivation of Latent HBV Hepatitis in Patients Under Neurosurgical Treatment . J Neuroinfect Dis 7:230. doi:10.4172/2314-7326.1000230
Copyright: © 2016 Ogawa Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Reactivation of hepatitis B virus (HBV) is a risk in the 350 million HBV carriers worldwide. HBV reactivation may cause hepatocellular carcinoma, cirrhosis, and fulminant hepatitis, and HBV reactivation accompanied with malignant tumor and/or chemotherapy is a critical problem for the patients with chronic HBV infection. In addition, multiple risk factors causing immunosuppressive state can also induce HBV reactivation, which includes a few cases of intrinsic cortisol over secretion as Cushing’s syndrome or very low-dose steroid treatment for hypopituitarism after pituitary surgeries.
Appropriate screening methods and the discussion for preventive supplementation of antiviral drugs for HBV reactivation are required. For patients with pituitary tumors precise operative procedures and careful treatment planning are essentially required to avoid HBV reactivation.